Characterization of Low Density Lipoprotein and Mechanism of the Pro Aggregant Effect Through Oxidant Stress and Lipid Exchange

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00932087

Acronym

ECLIPSE

Enrollment

Registered

2009-07-02

Start date

2009-02-28

Completion date

2010-01-31

Last updated

2010-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Metabolic Syndrome

Keywords

Platelet function, diabetes, metabolic syndrome

Brief summary

Case control design: lipidomic study in 12 type 2 diabetics with metabolic syndrome, 12 metabolic syndrome without diabetes, 12 subjects with type 1 diabetes and 12 controls

Interventions

PROCEDUREBlood sample

Blood sample for lipidomic study

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

30 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* statin and fibrate Wash out for one week * HbA1c\>7% and \<12% (Arms 1 and 3) * HbA1c\<6% (Arms 2 and 4) * Metabolic sd according NCEP III (3 out 4 criteria) (Arms 1 and 2)

Exclusion criteria

* secondary CV prevention

Design outcomes

Primary

Measure	Time frame
Level of plasma isoprostane and lipoperoxides	at baseline

Secondary

Measure	Time frame
TXA2 and PF4 levels after platelet activation of control platelet exposed to LDL	2 hours

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026